Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base.

Purpose Evidence from studies of other malignancies has indicated that aggressive local treatment (LT), even in the presence of metastatic disease, is beneficial. Against a backdrop of stagnant mortality rates for metastatic urothelial carcinoma of the bladder (mUCB) at presentation, we hypothesized that high-intensity LT of primary tumor burden, defined as the receipt of radical cystectomy or ≥ 50 Gy of radiation therapy delivered to the bladder, affects overall survival (OS). Patients and Methods We identified 3,753 patients within the National Cancer Data Base who received multiagent systemic chemotherapy combined with high-intensity versus conservative LT for primary mUCB. Patients who received no LT, transurethral resection of the bladder tumor alone, or < 50 Gy of radiation therapy delivered to the bladder were included in the conservative LT group. Inverse probability of treatment weighting (IPTW) -adjusted Kaplan-Meier curves and Cox regression analyses were used to compare OS of patients who received high-intensity versus conservative LT. Results Overall, 297 (7.91%) and 3,456 (92.09%) patients with mUCB received high-intensity and conservative LT, respectively. IPTW-adjusted Kaplan-Meier curves showed that median OS was significantly longer in the high-intensity LT group than in the conservative LT group (14.92 [interquartile range, 9.82 to 30.72] v 9.95 [interquartile range, 5.29 to 17.08] months, respectively; P < .001). Furthermore, in IPTW-adjusted Cox regression analysis, high-intensity LT was associated with a significant OS benefit (hazard ratio, 0.56; 95% CI, 0.48 to 0.65; P < .001). Conclusion We report an OS benefit for individuals with mUCB treated with high-intensity versus conservative LT. Although the findings are subject to the usual biases related to the observational study design, these preliminary data warrant further consideration in randomized controlled trials, particularly given the poor prognosis associated with mUCB.

[1]  F. Montorsi,et al.  A Multi-institutional Analysis of Perioperative Outcomes in 106 Men Who Underwent Radical Prostatectomy for Distant Metastatic Prostate Cancer at Presentation. , 2016, European urology.

[2]  S. Parikh,et al.  Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: The M.D. Anderson Cancer Center Experience. , 2016, Urologic oncology.

[3]  Tyler J. VanderWeele,et al.  Sensitivity Analysis Without Assumptions , 2015, Epidemiology.

[4]  C. Faivre-Finn,et al.  Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial , 2015, The Lancet.

[5]  P. Hegde,et al.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.

[6]  T. Choueiri,et al.  Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. , 2014, European urology.

[7]  P. Schellhammer,et al.  Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. , 2014, European urology.

[8]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[9]  P. Austin.  The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments , 2013, Statistics in medicine.

[10]  A. Zietman,et al.  Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. , 2013, European urology.

[11]  KyungMann Kim,et al.  Contrasting treatment‐specific survival using double‐robust estimators , 2012 .

[12]  P. Austin.  Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples , 2009, Statistics in medicine.

[13]  N. Shakhssalim,et al.  Palliative treatment of intractable hematuria in context of advanced bladder cancer: a systematic review. , 2009, Urology journal.

[14]  W. Meinhardt,et al.  Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[15]  R. Kaplan,et al.  Bone marrow cells in the ‘pre-metastatic niche’: within bone and beyond , 2007, Cancer and Metastasis Reviews.

[16]  Hiroyuki Aburatani,et al.  Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis , 2006, Nature Cell Biology.

[17]  Joon-ha Ok,et al.  Medical and surgical palliative care of patients with urological malignancies. , 2005, The Journal of urology.

[18]  A. Pycha,et al.  Four years experience in bladder preserving management for muscle invasive bladder cancer. , 2005, European urology.

[19]  D. Kroepfl,et al.  Radical cystectomy in patients aged ≥ 75 years: an updated review of patients treated with curative and palliative intent , 2005, BJU international.

[20]  Stephen R Cole,et al.  Adjusted survival curves with inverse probability weights , 2004, Comput. Methods Programs Biomed..

[21]  H. van Tinteren,et al.  Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  D. Roychowdhury,et al.  Health-related quality-of-life parameters as independent prognostic factors in advanced or metastatic bladder cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  N. Munshi,et al.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. , 2001, The New England journal of medicine.

[24]  R. Sylvester,et al.  Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial , 2001, The Lancet.

[25]  D. Bajorin,et al.  Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. , 2001, The Journal of urology.

[26]  J. Bacik,et al.  Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  I. Tannock,et al.  A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  S Paget,et al.  THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .

[29]  The Cancer Genome Atlas Research Network,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[30]  A. Kibel,et al.  Radiotherapy with or Without Chemotherapy in Muscle-Invasive Bladder Cancer , 2012 .

[31]  T. Choueiri,et al.  The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. , 2011, The Journal of urology.

[32]  E. Trimble,et al.  Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis. , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  H. Scher.  A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1992, The Journal of urology.

[34]  L. Coia,et al.  Palliative radiation therapy. , 1985, Seminars in oncology.

[35]  D. Hosmer,et al.  A review of goodness of fit statistics for use in the development of logistic regression models. , 1982, American journal of epidemiology.